BMT-090605 hydrochloride,99.09%

产品编号:Bellancom-101290A| CAS NO:2231664-45-0| 分子式:C21H25ClN4O2| 分子量:400.90

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-101290A
5600.00 杭州 北京(现货)
Bellancom-101290A
8900.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

BMT-090605 hydrochloride

产品介绍 BMT-090605 hydrochloride 是一种有效的选择性连接蛋白-2 相关激酶 1 (AAK1) 抑制剂,IC50 值为 0.6 nM。BMT-090605 hydrochloride 显示抗伤害活性。BMT-090605 hydrochloride 抑制 BMP-2 诱导蛋白激酶 (BIKE) 和细胞周期蛋白 G 相关激酶 GAK,IC50 值分别为 45 nM 和 60 nM。BMT-090605 hydrochloride 可用于神经性疼痛的研究。
生物活性

BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain.

体外研究

BMT-090605 hydrochloride shows AAK1inhibitory activity with an IC50 of 0.63 nM.
BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

BMT-090605 hydrochloride(intrathecal; 0.3-3 µg/rat) causes antinociception by inhibiting AAK1 in the spinal cord.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (chronic constriction injury (CCI) model)
Dosage: 0.3-3 µg/rat
Administration: Intrathecal
Result: Caused a dose-dependent reduction in thermal hyperalgesia.
体内研究

BMT-090605 hydrochloride(intrathecal; 0.3-3 µg/rat) causes antinociception by inhibiting AAK1 in the spinal cord.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (chronic constriction injury (CCI) model)
Dosage: 0.3-3 µg/rat
Administration: Intrathecal
Result: Caused a dose-dependent reduction in thermal hyperalgesia.
性状Solid
溶解性数据
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服